Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma

Molecular targeted therapy for advanced hepatocellular carcinoma (HCC) has changed markedly. Although sorafenib was used in clinical practice as the first molecular targeted agent in 2007, the SHARPE and Asian-Pacific trials demonstrated that sorafenib only improved overall survival (OS) by approxim...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ziyu, Lin, Yan, Zhang, Jinyan, Zhang, Yumei, Li, Yongqiang, Liu, Zhihui, Li, Qian, Luo, Ming, Liang, Rong, Ye, Jiazhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827249/
https://www.ncbi.nlm.nih.gov/pubmed/31684985
http://dx.doi.org/10.1186/s13046-019-1412-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827249/
https://www.ncbi.nlm.nih.gov/pubmed/31684985
http://dx.doi.org/10.1186/s13046-019-1412-8

Ejemplares similares